Description: EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices. Launched in January 2020, EQRx is purpose-built, at scale, with a growing catalog of medicines in development in high-cost drug categories and emerging partnerships with leading payers and providers. Leveraging cutting-edge science and technology and strategic partnerships with stakeholders from across the healthcare system, EQRx aims to provide innovative, patent-protected medicines more efficiently and cost-effectively than ever before.
Home Page: www.eqrx.com
EQRX Technical Analysis
50 Hampshire Street
Cambridge,
MA
02139
United States
Phone:
617 315 2255
Officers
| Name | Title |
|---|---|
| Mr. Alexis A. Borisy A.M. | Founder & Exec. Chairman of Board of Directors |
| Ms. Melanie I. Nallicheri | CEO & Director |
| Ms. Jamilu E. Rubin | Chief Financial Officer |
| Dr. Eric E. Hedrick M.D. | Chief Physician Exec. |
| Mr. Robert Forrester LL.B. | Co-Founder & Advisor |
| Dr. Peter B. Bach M.D., MAPP | Co-Founder & Advisor |
| Sir Andrew Dillon CBE | Co-Founder & Advisor |
| Mr. Daniel Hoey | Chief of Technical Operations |
| Ms. Dina Ciarimboli J.D. | Gen. Counsel & Corp. Sec. |
| Ms. Rona Anhalt | Chief People Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.9978 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-12-20 |
| Fiscal Year End: | December |
| Full Time Employees: | 240 |